Novo Nordisk A/S traded at 247.00 this Thursday March 12th, decreasing 2.80 or 1.12 percent since the previous trading session. Looking back, over the last four weeks, Novo Nordisk A/S lost 20.48 percent. Over the last 12 months, its price fell by 52.95 percent. Looking ahead, we forecast Novo Nordisk A/S to be priced at 235.06 by the end of this quarter and at 200.39 in one year, according to Trading Economics global macro models projections and analysts expectations.
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.